Novo Nordisk is likely to draw investor attention on Monday after the company said it is moving forward with the oral and subcutaneous forms of its investigational obesity drug amycretin following early clinical studies showing up to 24.

Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli Lilly began marketing its rival product Mounjaro in the world's most populous nation.

Shares in two companies slide as Danish drugmaker accuses US telehealth group of deceptively marketing replica treatments